Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Latest Information Update: 21 May 2022
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 10 May 2022 Status changed from recruiting to discontinued due to difficulty of patient recruitment.
- 21 Jul 2016 New trial record